Company VolitionRx Limited

Equities

VNRX

US9286611077

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for VolitionRx Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing

Market Closed - Nyse Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.7057 ^USD	+3.60%		-3.01%	-1.58%

May. 14	Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024
May. 13	VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Number of employees: 108

USD in Million	Weight	2023	Weight	Delta
Blood Tests 77.2 %	68.9 %	1	77.2 %	+183.64%
Service 22.6 %	30.2 %	0	22.6 %	+89.73%
Royalty 0.2 %	1.0 %	0	0.2 %	-52.97%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	1	100.0 %	+153.04%

Managers	Title	Age	Since
Cameron Reynolds CEO	Chief Executive Officer	53	11-10-05
Terig Hughes DFI	Director of Finance/CFO	54	21-01-31
Gaetan Michel COO	Chief Operating Officer	51	21-01-31
Mark Eccleston CTO	Chief Tech/Sci/R&D Officer	42	-
Jacob Micallef CTO	Chief Tech/Sci/R&D Officer	67	14-12-31
Scott Powell IRC	Investor Relations Contact	51	14-04-30
Louise Batchelor IRO	Public Communications Contact	-	16-04-13
Terry Kelly PRN	Corporate Officer/Principal	-	20-02-29
Gael Forterre PRN	Corporate Officer/Principal	43	21-01-31
Rodney Rootsaert SEC	Corporate Secretary	52	11-10-05

Members of the board	Title	Age	Since
Cameron Reynolds CEO	Chief Executive Officer	53	11-10-05
Martin Faulkes CHM	Chairman	80	11-10-05
Guy Innes BRD	Director/Board Member	67	11-10-05
Alan Colman BRD	Director/Board Member	75	11-10-05
Edward Futcher BRD	Director/Board Member	69	16-06-22
Phillip Barnes BRD	Director/Board Member	62	19-10-08
Kim Nguyen BRD	Director/Board Member	47	21-03-24
Mickie Henshall BRD	Director/Board Member	52	22-08-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	82,824,476	63,109,085 ( 76.20 %)	0	76.20 %

Name	Equities	%	Valuation
Cotterford Co. Ltd. 14.63 %	12,005,332	14.63 %	11 M $
Lagoda Investment Management LP 6.182 %	5,073,242	6.182 %	5 M $
Guy Innes 2.724 %	2,235,175	2.724 %	2 M $
Martin Faulkes 2.373 %	1,947,682	2.373 %	2 M $
Cameron Reynolds 1.559 %	1,279,261	1.559 %	1 M $
Concord International, Inc. 1.228 %	1,007,718	1.228 %	896 869 $
Vanguard Global Advisers LLC 0.7752 %	636,167	0.7752 %	566 189 $
Geode Capital Management LLC 0.7523 %	617,366	0.7523 %	549 456 $
BlackRock Institutional Trust Co. NA 0.6889 %	565,408	0.6889 %	503 213 $
Jacob Micallef 0.4285 %	351,628	0.4285 %	312 949 $

VolitionRX Ltd.

1489 West Warm Springs Road Suite 110

89014, Henderson

http://www.volition.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7057 USD

Average target price

3.633 USD

Spread / Average Target

+414.85%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
VOLITIONRX LIMITED	-1.58%	58.45M
EXACT SCIENCES CORPORATION	-38.56%	8.39B
GUARDANT HEALTH, INC.	+0.18%	3.32B
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.48B
BGI GENOMICS CO., LTD.	-18.21%	2.06B
VERACYTE, INC.	-24.57%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.15B
SEEGENE, INC.	-7.64%	704M
CAREDX, INC	+8.42%	678M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	508M

Bio Diagnostics & Testing